» Top-Line Results Of Boceprevir Phase II Study Showed High Rate Of Sustained Response (SVR) In Genotype 1 Treatment-Naive Hepatitis C Patients
Schering-Plough Corporation (NYSE: SGP) reported top-line results from a planned interim analysis of a Phase II study of boceprevir, its investigational oral hepatitis C protease inhibitor. The…